Currently Viewing:
Currently Reading
AJMC in the Press, October 14, 2016
October 14, 2016 – AJMC Staff
Nearly Half of Pregnant Women Gained More Weight Than Recommended in 2015
October 13, 2016 – Mary Caffrey
What We're Reading: US Healthcare System Ranked 50th of 55 in Efficiency
October 04, 2016 – AJMC Staff
Medicaid Coverage Steadies, Private Managed Care Remains Significant
October 02, 2016 – Jackie Syrop
What We're Reading: Treasury Lost Funds in Favor of ACA Insurers
September 30, 2016 – AJMC Staff
AJMC in the Press, September 30, 2016
September 30, 2016 – AJMC Staff
Test Hepatitis C Patients for Hepatitis B Before Treatment, Panel Advises
September 26, 2016 – Christina Mattina
Clinical Trial Pioneers Transplantation of Hepatitis C-Infected Kidneys
September 24, 2016 – Christina Mattina
What We're Reading: CDC Reports Rising Use of Powerful Antibiotics
September 20, 2016 – AJMC Staff

AJMC in the Press, October 14, 2016

AJMC Staff
Coverage of our peer-reviewed research in the healthcare and mainstream press.
In the October 3, 2016, edition of Medical Economics, Mark L. Fuerst discussed the commentary in a special issue of The American Journal of Managed Care on novel direct-acting antivirals (DAAs). Darius Lakdawalla, PhD, of the University of Southern California’s Schaeffer Center for Health Policy and Economics, wrote that cost-sharing plans that impose large out-of-pocket costs on DAAs for patients with hepatitis C virus (HCV) are “suboptimal solutions,” because they impose financial burdens on patients “at a time when they are least able to cope with them.” For the rest of the special issue on policy questions surrounding HCV treatment and cost-sharing, click here.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up